Events
24. September 2024, 10:00 bis 10:00
Johannes Karges, Faculty of Chemistry and Biochemistry, Ruhr-Universität Bochum/Germany
Seminar
The Platinum(II) complexes cisplatin and its derivatives dominate the field of anticancer chemotherapeutic agents. Despite their clinical success, these compounds are associated with severe side effects (i.e., nerve and kidney damage, nausea, vomiting, bone marrow suppression). To overcome these drawbacks, increasing research efforts are devoted towards Platinum(IV) complexes as prodrugs. These compounds are ideally inactive under physiological conditions but are reduced into their analogous Platinum(II) therapeutically active compounds within the cancerous cells. Typically, the reduction is caused by reducing agents such as glutathione, metallothionein, or ascorbic acid which are present in high levels within cancer cells.[1] However, as these agents are also available in healthy cells, this mechanism of action is associated with poor selectivity and low efficiency. To overcome this limitation, this presentation will focus on the tumor-targeted delivery and selective activation of Platinum(IV) prodrugs with light or ultrasound for anticancer therapy.[2-3] The ability to activate these Platinum(IV) prodrugs on demand allows for an anticancer treatment with high precision and selectivity.
[1] J. Karges, ChemNanoMat 2023, 9, e202300295.
[2] D. Wei, Y. Huang, B. Wang, L. Ma, J. Karges, H. Xiao, Angew. Chem. Int. Ed. 2022, 61, e202201486.
[3] G. Liang, T. Sadhukhan, S. Banerjee, D. Tang, H. Zhang, M. Cui, N. Montesdeoca, J. Karges, H. Xiao, Angew. Chem. Int. Ed. 2023, 62, e202301074.
Veranstaltung Details
- Veranstaltungsort
-
SEM.R. DB gelb 05 B
1040 Wien
Wiedner Hauptstraße 8-10/E134 - Veranstalter
-
IAP
Manuela Marik
marik@iap.tuwien.ac.at - Öffentlich
- Ja
- Kostenpflichtig
- Nein
- Anmeldung erforderlich
- Nein